MX2019013700A - Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand. - Google Patents

Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand.

Info

Publication number
MX2019013700A
MX2019013700A MX2019013700A MX2019013700A MX2019013700A MX 2019013700 A MX2019013700 A MX 2019013700A MX 2019013700 A MX2019013700 A MX 2019013700A MX 2019013700 A MX2019013700 A MX 2019013700A MX 2019013700 A MX2019013700 A MX 2019013700A
Authority
MX
Mexico
Prior art keywords
complications
treatment
compositions
methods
von willebrand
Prior art date
Application number
MX2019013700A
Other languages
English (en)
Inventor
C Gilbert James
Zhu Shuhao
Original Assignee
Band Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Band Therapeutics Llc filed Critical Band Therapeutics Llc
Publication of MX2019013700A publication Critical patent/MX2019013700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/316—Phosphonothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención proporciona agentes protectores del VWF, entre los que se incluyen aptámeros y anticuerpos para el tratamiento y/o mejora de las complicaciones o trastornos que se derivan de la unión o función anormal del VWF.
MX2019013700A 2017-05-19 2018-05-18 Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand. MX2019013700A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508530P 2017-05-19 2017-05-19
US201862638579P 2018-03-05 2018-03-05
PCT/US2018/033376 WO2018213697A1 (en) 2017-05-19 2018-05-18 Compositions and methods for the treatment of complications and disorders relating to von willebrand factor

Publications (1)

Publication Number Publication Date
MX2019013700A true MX2019013700A (es) 2020-01-15

Family

ID=64274836

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013700A MX2019013700A (es) 2017-05-19 2018-05-18 Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand.

Country Status (11)

Country Link
US (2) US11060094B2 (es)
EP (1) EP3624801A4 (es)
JP (2) JP7317805B2 (es)
KR (1) KR20200008122A (es)
CN (2) CN117487811A (es)
AU (1) AU2018269935B2 (es)
CA (1) CA3058001A1 (es)
IL (1) IL269641A (es)
MX (1) MX2019013700A (es)
TW (1) TWI806868B (es)
WO (1) WO2018213697A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230038761A1 (en) * 2020-02-04 2023-02-09 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)
US20240002861A1 (en) * 2020-11-24 2024-01-04 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
US20220305171A1 (en) * 2021-03-24 2022-09-29 Aleo Bme, Inc. Compositions comprising fluid gels for tissue separation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514984A (pt) * 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US7563601B1 (en) * 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
US20110118187A1 (en) * 2006-10-19 2011-05-19 Duke University Reversible platelet inhibition
WO2008150495A2 (en) 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
AU2015250584A1 (en) * 2014-04-24 2016-12-15 Ribomic Inc. Aptamer for bonding to autotaxin and inhibiting biological activity of autotaxin, and use for same
JP6544750B2 (ja) * 2015-03-06 2019-07-17 タグシクス・バイオ株式会社 Ｄｎａアプタマーの安定化法
SG11201803631YA (en) 2015-10-30 2018-05-30 Tagcyx Biotechnologies DNA aptamer that binds to vWF

Also Published As

Publication number Publication date
TW201900877A (zh) 2019-01-01
CN110520128B (zh) 2023-11-14
CN117487811A (zh) 2024-02-02
TWI806868B (zh) 2023-07-01
CN110520128A (zh) 2019-11-29
JP7317805B2 (ja) 2023-07-31
JP2020522566A (ja) 2020-07-30
AU2018269935B2 (en) 2024-05-16
RU2019136508A3 (es) 2022-02-14
AU2018269935A1 (en) 2019-11-28
JP2023093535A (ja) 2023-07-04
RU2019136508A (ru) 2021-06-22
IL269641A (en) 2019-11-28
EP3624801A1 (en) 2020-03-25
KR20200008122A (ko) 2020-01-23
US11060094B2 (en) 2021-07-13
US20210292763A1 (en) 2021-09-23
WO2018213697A1 (en) 2018-11-22
EP3624801A4 (en) 2021-02-24
US20200165612A1 (en) 2020-05-28
CA3058001A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
JOP20220245A1 (ar) أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
NZ738008A (en) Tigit-binding agents and uses thereof
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
MX2019009117A (es) Anticuerpos anti alfa-sinucleina y usos de los mismos.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12019502002A1 (en) Combination theraphy
PH12018502586A1 (en) Anti-coagulation factor xi antibodies
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12018501525A1 (en) Tgfbeta 2 antibodies
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
MX2019013700A (es) Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand.
TW201713686A (en) Methods for preparing modified von Willebrand factor
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
PH12019502694A1 (en) Anti-trkb antibodies
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
MX2021004804A (es) Compuestos organolepticos novedosos.
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
MX2018008731A (es) Compuestos organolepticos novedosos.
MX2017016617A (es) Compuestos organolepticos novedosos.
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств